



BioLineRx to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York

September 2, 2014

JERUSALEM--(BUSINESS WIRE)--Sep. 2, 2014-- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky, Ph.D., and its Chief Financial and Operating Officer, Philip Serlin, will be presenting at the 16th Annual Rodman & Renshaw Global Investment Conference at the New York Palace Hotel in New York City.

The BioLineRx presentation is scheduled to start at 11:15 a.m. EDT on Wednesday, September 10, 2014. A live audio webcast of the presentation will be available online at the investor page of the [Company's website](#). An archive of the event will also be available for those unable to listen live.

In addition, any investors attending the conference that wish to meet with Dr. Savitsky and Mr. Serlin for a one-on-one meeting should contact Lily Khaykina at LK@rodm.com.

About BioLineRx

BioLineRx is a publicly-traded, clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates. The Company in-licenses novel compounds primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.

BioLineRx's current portfolio consists of a variety of clinical and pre-clinical projects, including: BL-1040 for prevention of pathological cardiac remodeling following a myocardial infarction, which has been out-licensed to Bellerophon BCM (f/k/a Ikaria) and is in the midst of a pivotal CE-Mark registration trial; BL-8040 for treating acute myeloid leukemia (AML) and other hematological indications, which is in the midst of a Phase 2 study; and BL-7010 for celiac disease, which is in the midst of a Phase 1/2 study.

For more information on BioLineRx, please visit www.bioglinerx.com or download the investor relations mobile device app, which allows users access to the Company's 'SEC documents, press releases, and events. BioLineRx's' IR app is available on the iTunes App Store as well as the Google Play Store.

Source: BioLineRx Ltd.

Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D., +1-212-375-2664
jdrumm@tiberend.com

or
Andrew Mielach, +1-212-375-2694
amielach@tiberend.com

or
Tsipi Haitovsky, +972-3-6240871
Public Relations
tsipihai5@gmail.com